Price
$496.07-0.09%Social Signal Score
Analyst Ratings
56 analystsRevenue
$3.33B+705.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Reshma Kewalramani
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,400
- Beta
- 0.32
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 12.99
Financials
Revenue
$3.33B+705.7%Net Income
$1.10BEBITDA
$1.39BFree Cash Flow
$1.01B+1857.0%EPS (diluted)
$4.31Shares Outstanding (diluted)
255.70M+4.4%Operating Expenses
$1.58BCash & Debt
$7.85BReturn of Capital
$473.80MRevenue by Segment (annual)
$11.97BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.07B | $3.95B | $15.46 |
| 2024 | $11.02B | $-535.60M | $-2.08 |
| 2023 | $9.87B | $3.62B | $14.05 |
| 2022 | $8.93B | $3.32B | $12.97 |
| 2021 | $7.57B | $2.34B | $9.09 |
| 2020 | $6.21B | $2.71B | $10.44 |
| 2019 | $4.16B | $1.18B | $4.58 |
| 2018 | $3.05B | $2.10B | $8.25 |
| 2017 | $2.49B | $263.48M | $1.06 |
| 2016 | $1.70B | $-112.05M | $-0.46 |
| 2015 | $1.03B | $-558.12M | $-2.32 |
| 2014 | $580.41M | $-738.55M | $-3.14 |
| 2013 | $1.21B | $-445.03M | $-1.98 |
| 2012 | $1.53B | $-107.03M | $-0.50 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $22.72
- Implied price
- $658.77
- Return from $504.73
- 5.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $327.53 — -35.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | -10.3% | -7.1% | -4.3% | -1.8% | 0.5% |
| 3.0% | -5.7% | -2.4% | 0.6% | 3.2% | 5.6% |
| 8.0% | -1.1% | 2.4% | 5.5% | 8.2% | 10.7% |
| 13.0% | 3.5% | 7.1% | 10.4% | 13.2% | 15.9% |
| 18.0% | 8.0% | 11.9% | 15.2% | 18.3% | 21.0% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-24.30%Social Signal Score
Mentions (30)
- Newszacks.com·23h ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (RSS)fool·1d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
View source ↗ - News (Marketaux)insidermonkey.com·3d ago·Positive
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets That makes Vertex Pharmaceu[+223 characters]
View source ↗ - Newszacks.com·4d ago·Neutral
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
View source ↗ - 4chan /biz/biz·5d ago·Positive
…-IBM Corporation----IBM----Arvind Krishna----$207.26 Billion 10----T-Mobile US, Inc.----TMUS----Srinivasan Gopalan----$174.82 Billion 11----Vertex Pharmaceuticals----VRTX----Reshma Kewalramani----$133.74 Billion 12----Snowflake Inc.----SNOW----Sridhar Ramaswamy----$116.41 Billion 13----Adobe Inc.----ADBE----Shantanu Narayen----$90.75 Billion 14----Cadence Design Systems, Inc.----CDNS----Anirudh Devgan----$89.27 Billion 15----FedEx Corporation----FDX----Raj Subramaniam----$68.01 Billion 16----Fle…
View source ↗ - News (RSS)economictimes·6d ago·Neutral
Vertex in funding talks with RapidCanvas, Supernova
View source ↗ - News (RSS)seekingalpha·6d ago·Negative
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
View source ↗ - Newszacks.com·11d ago·Neutral
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.
View source ↗ - News (RSS)fool·11d ago·Positive
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
View source ↗ - Newszacks.com·13d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·17d ago·Positive
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
View source ↗ - News (RSS)financialpost·18d ago·Negative
Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) […]
View source ↗ - News (RSS)seekingalpha·21d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·21d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·24d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·26d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
View source ↗ - Newszacks.com·27d ago·Neutral
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
View source ↗ - Newszacks.com·27d ago·Neutral
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News (RSS)fool·31d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? They could both outperform the market over the medium term, but one appears to have a clear edge.
View source ↗ - Newszacks.com·33d ago·Neutral
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)fool·45d ago·Positive
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.
View source ↗ - News (RSS)yahoo·47d ago·Positive
Are Wall Street Analysts Bullish on Vertex Stock?
View source ↗ - News (RSS)investing·47d ago·Neutral
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD
View source ↗ - News (RSS)yahoo·52d ago·Neutral
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
View source ↗ - News (RSS)seekingalpha·52d ago·Positive
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
View source ↗ - News (RSS)investing.com·56d ago·Neutral
Why is Vertex Pharmaceuticals stock surging today?
View source ↗ - News (Alpha Vantage)ETF Database·75d ago·Positive
T. Rowe Price's Love Says Small-Cap Earnings Are Turning Jodi Love, lead portfolio manager of the T. Rowe Price Small-Mid Cap ETF (TMSL), believes that small-cap earnings are turning around after 10 quarters of declines, with estimates now pointing to accelerating growth. She notes that small and mid-cap stocks are trading at a significant discount to large caps, offering substantial room for growth. Love's fund, TMSL, has seen strong performance and capitalizes on this shift by investing in "pi
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $4.76 per share
Typical surprise -0.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$4.73 vs $4.74miss
- Mon, May 4$4.47 vs $4.24beat
- Thu, Feb 12$5.03 vs $5.11miss
- Mon, Nov 3$4.80 vs $4.57beat
- Mon, Aug 4$4.52 vs $4.29beat
- Mon, May 5$4.06 vs $4.25miss
Estimates and results for VRTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VRTX officers and directors.
- Bought
- —
- Sold
- $69.3m
0 trades
50 trades
- Tatsis Ouraniasold
- Mckechnie Duncansold
- Liu Joysold
- Bozic Carmensold
- Bozic Carmensold
- Bozic Carmensold
- Bozic Carmensold
- Bozic Carmensold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- David Taylorhouse · OH02 · disclosed Sep 7, 2026 (12d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- David J. Taylorhouse · OH02 · disclosed Feb 3, 2026 (5d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (39d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- David J. Taylorhouse · OH02 · disclosed Sep 3, 2025 (27d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (245d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (64d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Byron Donaldshouse · FL19 · disclosed Apr 15, 2025 (26d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Apr 15, 2025 (26d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (32d later)Buy$15,001 - $50,000
- Jefferson Shrevehouse · IN06 · disclosed Mar 9, 2025 (13d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2024 (21d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.